USA - NASDAQ:SILO - US82711P2011 - Common Stock
The current stock price of SILO is 0.5598 USD. In the past month the price decreased by -18.16%. In the past year, price decreased by -53.74%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.68 | 405.55B | ||
AMGN | AMGEN INC | 13.7 | 160.87B | ||
GILD | GILEAD SCIENCES INC | 15.87 | 152.38B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 24.61 | 106.87B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 63.14B | ||
REGN | REGENERON PHARMACEUTICALS | 12.67 | 61.27B | ||
ARGX | ARGENX SE - ADR | 91.01 | 51.63B | ||
ONC | BEONE MEDICINES LTD-ADR | 5.11 | 34.76B | ||
INSM | INSMED INC | N/A | 35.04B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.28B | ||
NTRA | NATERA INC | N/A | 24.94B | ||
BIIB | BIOGEN INC | 8.93 | 20.97B |
Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. The company is headquartered in Sarasota, Florida. The company went IPO on 2012-01-05. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
SILO PHARMA INC
677 N Washington Blvd
Sarasota FLORIDA US
Employees: 3
Phone: 17184009031
The current stock price of SILO is 0.5598 USD. The price decreased by -7.03% in the last trading session.
The exchange symbol of SILO PHARMA INC is SILO and it is listed on the Nasdaq exchange.
SILO stock is listed on the Nasdaq exchange.
SILO PHARMA INC (SILO) has a market capitalization of 7.46M USD. This makes SILO a Nano Cap stock.
SILO PHARMA INC (SILO) currently has 3 employees.
SILO PHARMA INC (SILO) has a support level at 0.55 and a resistance level at 0.67. Check the full technical report for a detailed analysis of SILO support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SILO does not pay a dividend.
SILO PHARMA INC (SILO) will report earnings on 2025-11-10.
SILO PHARMA INC (SILO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.02).
The outstanding short interest for SILO PHARMA INC (SILO) is 2.47% of its float. Check the ownership tab for more information on the SILO short interest.
ChartMill assigns a fundamental rating of 3 / 10 to SILO. No worries on liquidiy or solvency for SILO as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months SILO reported a non-GAAP Earnings per Share(EPS) of -1.02. The EPS increased by 12.91% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -73.58% | ||
ROE | -99.55% | ||
Debt/Equity | 0 |